Baseline comorbidities in a population-bases cohort of rheumatoid arthritis patients receiving biological therapy : date from the Australian Rheumatology Association database

Briggs, Andrew M., March, Lyn, Lassere, Marissa, Reid, Christopher, Henderson, Lyndall, Murphy, Bridie, Van Den Haak, Rosemary, Rischin, Adam, Staples, Margaret and Buchbinder, Rachelle 2009, Baseline comorbidities in a population-bases cohort of rheumatoid arthritis patients receiving biological therapy : date from the Australian Rheumatology Association database, International journal of rheumatology, vol. 2009, pp. 1-8.

Attached Files
Name Description MIMEType Size Downloads

Title Baseline comorbidities in a population-bases cohort of rheumatoid arthritis patients receiving biological therapy : date from the Australian Rheumatology Association database
Author(s) Briggs, Andrew M.
March, Lyn
Lassere, Marissa
Reid, Christopher
Henderson, Lyndall
Murphy, Bridie
Van Den Haak, Rosemary
Rischin, Adam
Staples, Margaret
Buchbinder, Rachelle
Journal name International journal of rheumatology
Volume number 2009
Start page 1
End page 8
Publisher Hindawi Publishing Corp
Place of publication New York, N.Y.
Publication date 2009
ISSN 1687-9260
1687-9279
Summary Aims: To describe the baseline characteristics of an Australian population-based cohort of rheumatoid arthritis (RA) patients commencing biological therapy.

Methods
: Descriptive analysis from the Australian Rheumatology Association Database (ARAD).

Results
: Up to October 2006, there were 681 RA patients taking biologics enrolled in ARAD. Baseline data were available for 624 (72% female, mean (SD) age 57.0 (12.5) years). Of these, 59.5% reported at least one comorbid condition, most commonly hypertension (35.7%) and osteoporosis (30.4%); 61 (9.8%) had a history of malignancy (35 nonmelanoma skin, 5 breast, 4 bowel, 5 cervix, 3 melanoma, 3 prostate and 1 each of lip, lung, myeloma, testis, uterus, vagina). Self-reported infections within the previous 6 months were common (71.5%).

Conclusions
: History of comorbidities, including recent infections, is common among Australian RA patients commencing biologics, and 10% have a history of malignancy. This may impact future evaluations of health outcomes among this population, including attribution of adverse events of biologic therapy.
Notes Article ID 861481
Language eng
Field of Research 110322 Rheumatology and Arthritis
Socio Economic Objective 920116 Skeletal System and Disorders (incl. Arthritis)
HERDC Research category C1 Refereed article in a scholarly journal
Copyright notice ©2009, Andrew M. Briggs et al.
Persistent URL http://hdl.handle.net/10536/DRO/DU:30024914

Document type: Journal Article
Collection: Public Health Research, Evaluation, and Policy Cluster
Connect to link resolver
 
Unless expressly stated otherwise, the copyright for items in DRO is owned by the author, with all rights reserved.

Versions
Version Filter Type
Access Statistics: 440 Abstract Views, 0 File Downloads  -  Detailed Statistics
Created: Fri, 05 Mar 2010, 11:09:10 EST by Sally Morrigan

Every reasonable effort has been made to ensure that permission has been obtained for items included in DRO. If you believe that your rights have been infringed by this repository, please contact drosupport@deakin.edu.au.